AACP
IMVT icon

Advantage Alpha Capital Partners’s Immunovant IMVT Stock Holding History

Advantage Alpha Capital Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,975
Closed -$427K – 169
2024
Q3 		$427K Buy
+14,975
New +$442K 0.1% 147

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Advantage Alpha Capital Partners's IMVT Position: Q4 2024 in Review

Advantage Alpha Capital Partners sold out of Immunovant (IMVT) in Q4 2024, closing a stake of 14,975 shares — an estimated $427K sold.

Advantage Alpha Capital Partners first reported a position in IMVT in Q3 2024 and held it in 1 quarter. The position peaked at $427K in Q3 2024. 186 funds tracked by Wall St. Rank hold IMVT as of Q4 2024.

  • Advantage Alpha Capital Partners reported no remaining Immunovant position as of Q4 2024 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 14,975 Immunovant shares in Q4 2024, an estimated $427K.
  • Advantage Alpha Capital Partners first reported a position in Immunovant in Q3 2024 and held it in 1 quarter.
  • Advantage Alpha Capital Partners's Immunovant position peaked at $427K in Q3 2024.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q4 2024.

Based on Advantage Alpha Capital Partners's 13F filing for Q4 2024, filed 11 Feb 2025.